Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,617 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar MK, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson S, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas Bisneto JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade MJ, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Major A, et al. Among authors: singh n. Blood Adv. 2023 Aug 22;7(16):4528-4538. doi: 10.1182/bloodadvances.2023010016. Blood Adv. 2023. PMID: 37026796 Free PMC article.
Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies.
Ghobadi A, Landmann JH, Carter A, Cooper ML, Selli ME, Chang J, Baker M, Miller CA, Ferraro F, Chen DY, Smith AM, LaValle TA, Duncavage EJ, Chou J, Tam V, Benoun JM, Nater J, Scholler N, Milletti F, Vezan R, Bot A, Rossi JM, Singh N. Ghobadi A, et al. Among authors: singh n. Blood Adv. 2022 Oct 25;6(20):5634-5640. doi: 10.1182/bloodadvances.2022007705. Blood Adv. 2022. PMID: 35858291 Free PMC article. No abstract available.
Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors.
Chang JF, Landmann JH, Chang TC, Selli ME, Tenzin Y, Warrington JM, Ritchey J, Hsu YS, Slade M, Gupta DK, DiPersio JF, Holehouse AS, Singh N. Chang JF, et al. Among authors: singh n. Cancer Discov. 2024 Nov 1;14(11):2109-2121. doi: 10.1158/2159-8290.CD-23-1393. Cancer Discov. 2024. PMID: 38980802
Antigen glycosylation regulates efficacy of CAR T cells targeting CD19.
Heard A, Landmann JH, Hansen AR, Papadopolou A, Hsu YS, Selli ME, Warrington JM, Lattin J, Chang J, Ha H, Haug-Kroeper M, Doray B, Gill S, Ruella M, Hayer KE, Weitzman MD, Green AM, Fluhrer R, Singh N. Heard A, et al. Among authors: singh n. Nat Commun. 2022 Jun 11;13(1):3367. doi: 10.1038/s41467-022-31035-7. Nat Commun. 2022. PMID: 35690611 Free PMC article.
Mechanisms of resistance to CAR T cell therapies.
Singh N, Orlando E, Xu J, Xu J, Binder Z, Collins MA, O'Rourke DM, Melenhorst JJ. Singh N, et al. Semin Cancer Biol. 2020 Oct;65:91-98. doi: 10.1016/j.semcancer.2019.12.002. Epub 2019 Dec 19. Semin Cancer Biol. 2020. PMID: 31866478 Free PMC article. Review.
Advances in CAR design.
Heard A, Chang J, Warrington JM, Singh N. Heard A, et al. Among authors: singh n. Best Pract Res Clin Haematol. 2021 Sep;34(3):101304. doi: 10.1016/j.beha.2021.101304. Epub 2021 Aug 26. Best Pract Res Clin Haematol. 2021. PMID: 34625230 Review.
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, Shyu A, Highfill SL, Price A, Zhao L, Peng L, Granda B, Ramones M, Lu XM, Christian DA, Perazzelli J, Lacey SF, Roy NH, Burkhardt JK, Colomb F, Damra M, Abdel-Mohsen M, Liu T, Liu D, Standley DM, Young RM, Brogdon JL, Grupp SA, June CH, Maude SL, Gill S, Ruella M. Singh N, et al. Nat Med. 2021 May;27(5):842-850. doi: 10.1038/s41591-021-01326-5. Epub 2021 Apr 22. Nat Med. 2021. PMID: 33888899 Free PMC article. Clinical Trial.
Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies.
Zheng S, Gillespie E, Naqvi AS, Hayer KE, Ang Z, Torres-Diz M, Quesnel-Vallières M, Hottman DA, Bagashev A, Chukinas J, Schmidt C, Asnani M, Shraim R, Taylor DM, Rheingold SR, O'Brien MM, Singh N, Lynch KW, Ruella M, Barash Y, Tasian SK, Thomas-Tikhonenko A. Zheng S, et al. Among authors: singh n. Blood Cancer Discov. 2022 Mar 1;3(2):103-115. doi: 10.1158/2643-3230.BCD-21-0087. Blood Cancer Discov. 2022. PMID: 35015683 Free PMC article.
11,617 results
You have reached the last available page of results. Please see the User Guide for more information.